Literature DB >> 15262499

Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.

Julia G Prado1, Sandra Franco, Tania Matamoros, Lidia Ruiz, Bonaventura Clotet, Luis Menéndez-Arias, Miguel Angel Martínez, Javier Martinez-Picado.   

Abstract

A two-serine insertion at position 69 (i69SS) of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) appears to be critical to enhance multi-nucleoside RT inhibitor resistance (MNR) in the sequence context of multiple zidovudine (AZT) resistance mutations (i.e., M41L, L210W, T215Y). In this study, we measured the replication capacity relative to the wild-type (WT) HIV-1 of a series of recombinant viruses carrying the i69SS in the background of a clinical isolate with MNR in which we introduced mutations D67N, Y215T, Y215S, or Y215N. In vitro measurements included replication kinetics and growth competition assays at different multiplicities of infection (MOI). While the addition of D67N had a minor effect on replication capacity, the reversion of Tyr-215 to Thr, Ser, or Asn was sufficient to increase the virus ability to replicate in a drug-free environment. The same genotypic changes at position 215 rendered the MNR virus susceptible to AZT and stavudine. Interestingly, the presence of the insertion together with mutation T215Y in an otherwise WT sequence background was not sufficient to confer high-level resistance to AZT, although its replication capacity was clearly impaired. Therefore, the RT residue 215 plays a critical role in both replication capacity and drug resistance of multidrug-resistant viruses containing the i69SS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262499     DOI: 10.1016/j.virol.2004.06.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 2.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 3.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 4.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

5.  HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.

Authors:  Moussa Thiam; Halimatou Diop-Ndiaye; Aminata Diaw Diouf; Nicole Vidal; Ousseynou Ndiaye; Ibrahima Ndiaye; Ndeye Fatou Ngom-Gueye; Sada Diallo; Oumy Diop Diongue; Makhtar Camara; Abdoulaye Seck; Souleymane Mboup; Coumba Toure-Kane
Journal:  J Clin Microbiol       Date:  2012-12-12       Impact factor: 5.948

6.  HLA-Cw*03-restricted CD8+ T-cell responses targeting the HIV-1 gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation.

Authors:  Isobella Honeyborne; Francisco M Codoñer; Alasdair Leslie; Gareth Tudor-Williams; Graz Luzzi; Thumbi Ndung'u; Bruce D Walker; Philip J Goulder; Julia G Prado
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

7.  In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants.

Authors:  Xiaodong Zhao; Enmei Liu; Fu-Ping Chen; Wayne M Sullender
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

8.  Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.

Authors:  Cristina Villena; Julia G Prado; Maria Carmen Puertas; Miguel Angel Martínez; Bonaventura Clotet; Lidia Ruiz; Neil T Parkin; Luis Menéndez-Arias; Javier Martinez-Picado
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

9.  Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

Authors:  Hans-Jürgen Stellbrink
Journal:  Core Evid       Date:  2010-06-15

10.  Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments.

Authors:  Hongyu Miao; Carrie Dykes; Lisa M Demeter; James Cavenaugh; Sung Yong Park; Alan S Perelson; Hulin Wu
Journal:  Bull Math Biol       Date:  2008-07-22       Impact factor: 1.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.